Treats serious infections caused by susceptible anaerobic bacteria. ANDA 216957, held by Glenmark Pharms Ltd. Clindamycin Hydrochloride.
As of Nov 16, 2026, ANDA 216957 (Clindamycin Hydrochloride), held by Glenmark Pharms Ltd, was first approved by FDA on Mar 10, 2023, with 0 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Clindamycin is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of colitis, as described in the BOXED WARNING, before selecting clindamycin, the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin).
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 10, 2023 | Original application | Approved | None posted |
| Clindamycin HydrochlorideEQ 75MG BASE · capsule;oral | Clindamycin Hydrochloride | Rx |
| Clindamycin HydrochlorideEQ 150MG BASE · capsule;oral | Clindamycin Hydrochloride | Rx |
| Clindamycin HydrochlorideEQ 300MG BASE · capsule;oral | Clindamycin Hydrochloride | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters